Bull, Bear & Beyond – Oryzon Genomics: executive interview

In this interview, we speak to Carlos Buesa, CEO of Oryzon Genomics, with a focus on the company’s top strategic priority, iadademstat, in first-line acute myeloid leukaemia (AML). We discuss the drug’s mechanism of action, Oryzon’s ongoing clinical programmes in AML – particularly in the first-line setting – and the interim data due to be presented at the EHA conference in June. We also explore the key unmet needs in first-line AML and how iadademstat is positioned to address them, as well as the broader opportunity for the drug, including its potential in sickle cell disease. Finally, we discuss the key expected milestones and next steps for iadademstat through 2026 and into 2027.

Oryzon Genomics is a Spanish biotech focused on epigenetics. Iadademstat is being explored for haematology-oncology, where the strategic priority is in first-line AML; there is potential for an accelerated approval pathway should clinical data continue to be supportive. It is also being evaluated in other indications, such as myelodysplastic syndrome, myeloproliferative neoplasms and sickle cell disease, as well as in small cell lung cancer. Central nervous system asset vafidemstat has completed a Phase IIb trial in borderline personality disorder and preparations are underway for Phase III. It is also currently involved in a Phase IIb trial for schizophrenia, and management is preparing for an additional Phase II trial in autism spectrum disorder.

Listen on your preferred podcast player below:

• Apple Podcast
• Spotify
• YouTube
• Zencastr

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.